Lexicon Pharmaceuticals LXRX Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months)?
- Lexicon Pharmaceuticals (LXRX) reported available-for-sale debt securities - unrealized loss position (<12 months) of $123.1M in Q1 2026.
- How has Lexicon Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months) changed year-over-year?
- Lexicon Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months) increased by 114.8% year-over-year, from $57.3M to $123.1M.
- What is the long-term trend for Lexicon Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months)?
- Over 2 years (2023 to 2025), Lexicon Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months) has grown at a -79.3% compound annual growth rate (CAGR), from $58.5M to $2.5M.